Hit-Product Scan, September 2026: Azelaic Acid Clears All Three Filters

The Signal: One Candidate Cleared All Three Filters

Our monthly hit-product scan screens Amazon US search data for three things at the same time: volume large enough to carry a brand, year-on-year growth pointing the same direction, and a listing base thin enough that a new entrant is not buying into a shelf that is already full.

In September 2026 exactly one candidate cleared all three: azelaic acid — 671,541 monthly searches, +208.1% year on year, against 349 live listings in the search result set [1][2].

That combination is unusual, and the contrast is easier to see than the claim. The candidates with real volume — magnetic eyelashes (2,878,349 searches) and colour-changing foundation (409,777) — sit in listing bases of 1,275 and 4,124, where search growth is absorbed by incumbents [1]. The candidate with the steepest headline growth this round, hair perfume spray (+8,480.5%), is an artefact of a very low base: 5,312 competing listings and a 0.54% purchase rate is volume without conversion and without room [1].

The September 2026 Numbers

Candidate	Monthly searches (US)	YoY	Live listings	Purchase rate	Avg. bid	Avg. price
Azelaic acid	671,541	+208.1%	349	6.06%	$6.22	$12.20
PDRN	157,941	+118.8%	3,272	not captured	not captured	not captured
Tranexamic acid	71,666	+57.3% *	715	not captured	not captured	not captured
Volufiline (watch)	815,181	+997.1%	337	9.43%	$2.39	$17.82
Colour-changing foundation (watch)	409,777	+638.0%	4,124	5.64%	$3.82	$18.87
Magnetic eyelashes (downgraded)	2,878,349	+36.0%	1,275	3.08%	$0.20	$16.95
Hair perfume spray (dropped)	173,584	+8,480.5% *	5,312	0.54%	$0.39	$19.67

* Low base, or the year-on-year comparison has not yet been re-verified in the same month — flagged rather than trusted [1][2]. "Not captured" means the field was not part of this round's pull; it is left empty rather than estimated.

Direction Check: On-Site Demand Has to Agree With Off-Site Interest

Amazon data shows what people search inside Amazon. Google Trends shows whether general interest is still rising or has already turned. Candidates that fail the second test get downgraded even when their Amazon volume still looks strong [3]:

• Volufiline — relative interest peaked at 84; the latest reading is 14 (week ending 6 September 2026), down 83% from peak with no recovery. On-site volume is still high (815,181 searches), so this is a closing window rather than a closed one: trial batches, no raw-material commitment.
• Hair perfume spray — 80 (19 April 2026) to 4 (20 September 2026), a 95% collapse. Dropped from the candidate list.
• Magnetic eyelashes — 72 to 29, still falling. Downgraded.
• Colour-changing foundation — 68 to 21, flat after the initial spike. Moved to watch-only; its brand-led query alone accounts for 874,102 searches against a 0.86% purchase rate, which is traffic that does not convert [1].

Azelaic acid did not need that second test this round, because its growth is visible inside the Amazon series itself: roughly 22,000 searches in 2022, 699,000 in July 2024, 217,984 in August 2025, 520,047 in June 2026 and 671,541 in August 2026 — three consecutive months at new highs [2]. The demand is also generic rather than brand-owned: the two largest brand queries in the cluster together account for about 26% of the main term's volume, leaving roughly three quarters of the search demand open [1].

The Ingredient Is the Easy Part: Where the Real Gap Sits

PDRN is the clearest example from this scan. 157,941 searches and +118.8% growth look like an open ingredient market, but the largest single query in that cluster is a brand name with 197,030 searches — more than the generic term itself. Demand is being pulled by one brand's marketing, not by an ingredient buyers are shopping for by name, and a private label brief built on "PDRN serum" would be competing for brand-loyal searches [1].

The gap sits one level down, in format: the PDRN stick query carries 28,816 searches and +1,913.7% year on year against only 261 live listings [1]. Anhydrous stick formats also remove most of the preservation and stability work that makes water-based polynucleotide serums expensive to hold stable — a manufacturing argument, and therefore a sourcing argument, rather than a marketing one.

Compliance Boundary: Azelaic Acid Is Not a Cosmetic Claim in Every Market

This is the part of the brief that decides whether the project is a cosmetics project at all. In the United States, azelaic acid 15% (Finacea, first approved in 1995) is a prescription-only product, labelled "Rx only" and indicated for the topical treatment of inflammatory papules and pustules of mild to moderate rosacea [4]. A cosmetic manufacturer can formulate with cosmetic-grade azelaic acid and support cosmetic claims; it cannot manufacture or substantiate a drug claim, and no brief should be written as though it could.

In practice that means:

• The brief states the destination market and the intended claim before formulation starts, not before artwork.
• Claims stay cosmetic — appearance, feel, texture, hydration, sensorial behaviour. No treatment, cure or condition language, in any language the SKU ships in.
• Whatever percentage or hero ingredient the artwork features has to match a documentation trail that already exists.

Where a brand wants a treatment-level claim, that is a drug pathway with a different manufacturer and a different regulatory owner. Better to say that at the brief stage than at the artwork stage.

What This Changes in a Private Label Brief

1. Azelaic acid moves to the top of the new-candidate list — as an ingredient brief, not a claim brief. The question to answer first is which format carries it: leave-on gel, jelly sheet, anhydrous stick or single-dose.
2. PDRN stays, but the brief changes shape — from "a serum because the category is a serum" to a stick or anhydrous format where the polynucleotide has fewer stability problems to survive.
3. Volufiline: trial quantities only. On-site demand is high while off-site interest keeps falling; buy for a sample run, not for inventory.
4. Tranexamic acid stays unverified until its year-on-year figure is confirmed against the same month in the prior year — treat +57.3% as directional until then.
5. Dropped this round: hair perfume spray, peptide lip treatment (brand-driven), exosome serums (search volume too thin), snail mucin (-37.3%), collagen serum (+24%), lip plumper (-18.5% with a $10 bid) and skin barrier (47,759 listings — saturated) [1].

Formats We Can Build Into Today

• Azelaic acid — cosmetic-grade nonanedioic acid, already in production in a jelly-gel sheet format (Seaweed Azelaic Acid VC Retinol Jelly Gel), and available as a custom gel or stick project.
• PDRN — polynucleotides across serums and masks (PDRN Peptide Serum | Private Label & OEM), with anhydrous stick formats (Private Label Multi Balm Stick) built on an existing line.
• Tranexamic acid — trans-4-aminomethylcyclohexanecarboxylic acid in serum and toner-pad formats.
• Brightening formats generally — vitamin C, niacinamide and arbutin systems, all in the current formula library of 90+ sheet and leave-on formats.

Production facts behind those lines: samples in 3–7 days, standard production about 20 days after confirmation (ODM 45–60 days; custom development 60–90 days), MOQ 500 units per SKU for private label, 1,000 units per SKU for standard catalogue items and 3,000+ units per SKU for custom formulation — manufactured in a 3,886 m² GMPC cleanroom, audited to ISO 22716:2007 (SGS CN19/31476) and US FDA CFSAN Cosmetic GMP (SGS CN19/31477) [5].

Request a quote or browse the formats we produce.

Method, Data Sources and Caveats

The scan is run on Amazon Brand Analytics top-search-term data for the US marketplace, read through our own tooling, and cross-checked against Google Trends for direction. Three limits are worth stating plainly:

1. Snapshot timing. The 2026-09 monthly ABA release had not refreshed when this scan ran on 25 September 2026, so the figures above are the latest available release (2026-08). This is "no new monthly data", not "no change" [1].
2. Relative, not absolute. Google Trends values are a relative index. They show direction and turning points; they do not show how many people searched [3].
3. Search demand is not purchase demand. A large search term with a thin listing base is an opening hypothesis, not a forecast — which is why every candidate above is paired with a listing count and, where captured, a purchase rate.